Work

Lorlatinib in frontline treatment of advanced ALK-positive non-small cell lung cancer: a highly efficient new standard of care but still challenging to manage

Year: 2025

Type: editorial

Source: Translational Lung Cancer Research

DOI: 10.21037/tlcr-24-903

Authors: Mylène Wespiser, Aurélie Swalduz, Maurice Pérol

Institution: Centre Léon Bérard

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Novocure, Ipsen, Daiichi Sankyo Europe

OpenAlex ID: W4406684561

Cites:

Cited by: 2

Related to: 10